Application of collateral dredging preparation in preparation of medicine for treating prostate diseases

By developing a traditional Chinese medicine composition composed of traditional Chinese medicines such as astragalus and honeysuckle, the problem of treating prostatic hyperplasia and prostatitis in the prior art has been solved, and the effective application of traditional Chinese medicine in modern medicine has been achieved, which has significantly improved the patient's symptoms and disease It has been verified in science.

CN119055733APending Publication Date: 2024-12-03LUNAN HOPE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310643741.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively treat prostatic hyperplasia and prostatitis. Traditional Chinese medicine has accurate efficacy and few toxic side effects, but it lacks systematic research and application in modern medicine.

Method used

Based on the existing Mailoushutong Granules/Pills, a traditional Chinese medicine composition was developed, mainly made of Astragalus, Honeysuckle, Yellow Cypress, Atractylodes, Scrophularia, Angelica sinensis, White Peony, Coix seed, centipede, scorpion, leech, and licorice. It can be prepared into clinically acceptable dosage forms such as pills, granules, tablets, etc. through steam distillation, water decoction, and ethanol extraction, and other methods, for the treatment of prostate diseases.

Benefits of technology

In clinical application, this traditional Chinese medicine composition significantly improves the clinical symptoms of prostatitis and prostatic hyperplasia. Through the effects of clearing heat and dampness, unblocking meridians and removing blood stasis, relieving qi and stagnation of liver meridians, the effect of invigorating qi and replenishing kidneys, removing blood stasis and unblocking orifices, and achieved the effect of invigorating qi and replenishing blood stasis and unblocking orifices. Significant therapeutic effects and verified in pathological experiments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses application of a collateral dredging preparation in preparation of a medicine for treating prostate diseases. The collateral dredging preparation is prepared from 12 raw medicinal materials including astragalus membranaceus, honeysuckle, golden cypress, rhizoma atractylodis, radix scrophulariae, angelica sinensis, radix paeoniae alba, coix seeds, centipedes, scorpio, leeches and liquorice, has the effects of clearing heat and promoting diuresis, dredging collaterals and dispersing blood stasis, relieving qi stagnation in liver channels, inducing diuresis and treating stranguria and digesting damp-heat in lower jiao, and all the medicinal materials are combined to jointly achieve the effects of tonifying qi and kidney, removing blood stasis and opening orifices, and have the effects of clearing heat and promoting diuresis. The traditional Chinese medicine composition is convenient to take, small in adverse reaction and wide in application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating prostate diseases, belonging to the technical field of traditional Chinese medicines. Background Art

[0002] Prostatitis, prostatic hyperplasia and prostate cancer are the three most common urological diseases in men.

[0003] Prostatic hyperplasia (BPH) is both a common disease and a difficult disease to treat. It is a disease caused by benign prostatic hyperplasia and manifested as lower urinary tract dysfunction. Its etiology is complex and caused by multiple factors. Most of them occur in elderly men. "Chinese Medicine Surgery" records that the pathological basis of this disease is kidney qi deficiency, poor qi transformation, poor blood circulation, and dysfunction of the kidney and bladder. It is mainly caused by spleen and kidney deficiency, qi stagnation and blood stasis, or damp heat accumulation. At present, there is still a lack of effective methods to treat prostatic hyperplasia, and Chinese medicine treatment has greater advantages.

[0004] Prostatitis refers to a group of diseases in which patients experience pain and discomfort in the pelvic area, abnormal urination, and local or systemic symptoms associated with the prostate under the action of pathogenic microorganisms and (or) non-infectious factors. Prostatitis is a common urogenital disease in men, with a population incidence of 30%-35%. Prostatitis is divided into 4 types: Type I is acute bacterial prostatitis (ABP), Type II is chronic bacterial prostatitis (CBP), Type III is chronic prostatitis (CP) / chronic pelvic pain syndrome (CPPS), and Type IV is asymptomatic prostatitis, of which Type III is further divided into Type IIIA (inflammatory) and Type IIIB (non-inflammatory). Prostatitis is a common disease in urology. With the acceleration of the pace of life and changes in living habits, the incidence rate is on the rise. Therefore, there are still many challenges in the diagnosis and treatment of prostatitis.

[0005] Chronic prostate disease (CP) is a common disease in urology. Studies have shown that the incidence rate in men over 35 years old is as high as 35-40%, and it is often manifested as urgent urination, frequent urination, painful urination, and difficulty urinating. It has the characteristics of high incidence, lingering and difficult to cure, and easy recurrence, which seriously affects the patient's quality of life and physical and mental health. It is also an important cause of male infertility. Damp-heat stagnation and blood stasis can easily lead to chronic prostatitis, and most of them are complex syndromes. Chronic prostatitis belongs to the categories of "sperm turbidity", "stranguria" and "leucorrhea" in traditional Chinese medicine. Its causes are mostly attributed to dampness, heat, blood stasis, and deficiency, and these factors often coexist at the same time, and the pathogenesis is often complicated. Among them, the most frequently occurring syndrome combination is damp-heat syndrome plus qi stagnation and blood stasis syndrome.

[0006] In recent years, with the continuous in-depth research on therapeutic drugs, the advantages of Chinese medicine with few side effects and good efficacy have gradually emerged. Chinese medicine has the advantages of precise efficacy, few toxic side effects, and overall regulation and improvement of the condition in the prevention and treatment of prostate diseases. In today's world where prevention and health care are emphasized, exploring the treatment of prostate diseases with Chinese medicine is undoubtedly of greater significance, and research in this area will surely have a broader prospect. Summary of the invention

[0007] The present invention is a further development of the use of the existing product "Mailuo Shutong Granules / Pills" based on its research. It is found that Mailuo Shutong Granules / Pills have the effects of relieving qi stagnation in the liver meridian, promoting diuresis and relieving stranguria, and digesting dampness and heat in the lower abdomen. Based on this effect, the inventor has conducted further research and development on Mailuo Shutong Granules / Pills and their formulations for the treatment of prostate diseases.

[0008] One of the purposes of the present invention is to provide a use of a Mailuoshutong preparation in the preparation of a drug for treating prostate diseases. The use of the present invention is discovered in clinical applications and has been confirmed by pharmacological experiments to have a broad application prospect.

[0009] The traditional Chinese medicine composition is mainly prepared from astragalus, honeysuckle, phellodendron, atractylodes, scrophularia, angelica, white peony root, coix seed, centipede, scorpion, leech and liquorice.

[0010] The prostate diseases described in the present invention include but are not limited to prostatitis, prostate hyperplasia and prostate cysts.

[0011] According to some embodiments, the prostatic hyperplasia described in the present invention is divided into blood stasis in the lower abdomen type, bladder damp-heat type, kidney yin deficiency type, kidney yang deficiency type or lung heat and qi stagnation type according to TCM dialectics, and the prostatitis described in the present invention is divided into damp-heat descending type, qi stagnation and blood stasis type, yin deficiency and hyperactivity of fire type, kidney yang deficiency type or spleen deficiency and dampness type according to TCM dialectics.

[0012] According to some embodiments, the prostatitis described in the present invention includes but is not limited to acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis / chronic pelvic pain syndrome and asymptomatic prostatitis.

[0013] The second object of the present invention is to provide the specific composition of the above-mentioned Mailuoshutong preparation, that is, the Mailuoshutong preparation is mainly prepared from the following raw materials:

[0014]

[0015] According to some embodiments, the Meridian Shutong preparation is mainly prepared from the following raw materials:

[0016]

[0017] According to some embodiments, the Meridian Shutong preparation is mainly prepared from the following raw materials:

[0018]

[0019]

[0020] The third object of the present invention is to provide a method for preparing the above-mentioned meridian dredging preparation. The raw medicinal material slices are subjected to steam distillation, water decoction, and ethanol reflux extraction to obtain an extract. After the extract is dried and crushed, it is mixed with fine powder of animal medicinal materials, and pharmaceutically acceptable excipients are added to prepare a clinically acceptable dosage form.

[0021] According to some embodiments, the clinically acceptable dosage form is one or more of pills, granules, tablets, pellets, micropills, and capsules.

[0022] The preparation method of the Mailuoshutong preparation of the present invention comprises the following steps:

[0023] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0024] B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 of the prescribed amount of Leech, Centipede and Scorpion, and combine them with the residue obtained in step A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoctions, filter and set aside;

[0025] C. Combine the aqueous solution after distillation in step A and the decoction in step B, concentrate to obtain a concentrate, add ethanol to make the alcohol content reach 60%-70%, let it stand for 24-36 hours to allow it to fully precipitate, collect the supernatant, filter, concentrate the filtrate under reduced pressure to recover ethanol to obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder;

[0026] D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside;

[0027] E. Mix the fine powder of medicinal material obtained in step D and the dry powder obtained in step C, add the volatile oil in step A, and prepare a clinically acceptable dosage form directly or by adding pharmaceutically acceptable excipients through conventional procedures.

[0028] Compared with the prior art, the present invention has achieved remarkable technical effects:

[0029] 1 The use of the Mailuo Shutong preparation described in the present invention in the treatment of prostate diseases is derived from user feedback. Some patients suffering from prostatitis or prostatic hyperplasia were found to have significantly improved clinical symptoms of prostatitis and prostatic hyperplasia after taking Mailuo Shutong Granules or Mailuo Shutong Pills.

[0030] 2 Clinical research results show that the use of this Chinese medicine composition can clear away heat and dampness, dredge the meridians and remove blood stasis, relieve qi stagnation in the liver meridians, promote diuresis and relieve stranguria, and digest dampness and heat in the lower abdomen. The combination of these medicines can replenish qi and tonify the kidney, remove blood stasis and open the orifices, thereby achieving good results in the treatment of prostatic hyperplasia and prostatitis, and at the same time has been verified to a certain extent in pathological experiments. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Comparison of white blood cell counts in prostatic fluid of rats in each group ( n=10) (Note: from left to right are blank group, model group, Qianlie Shutong capsule group, low-dose group of Example 1, medium-dose group of Example 1, high-dose group of Example 1, comparative example 1 group, comparative example 2 group, among which compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, @ P<0.05, @@ P<0.01; compared with the Qianlie Shutong capsule group, # P<0.05, ## P<0.01; compared with the dosage group in Example 1, $ P<0.05, $$ P<0.01. ) Figure 2 Comparison of urine output among groups of rats ( n=10) Specific embodiments

[0031] The present invention is further described below by way of examples. It should be correctly understood that the examples of the present invention are only some representative formulations, and their purpose is only to illustrate the present invention, rather than to limit the present invention. Therefore, simple improvements to the present invention under the premise of the method of the present invention all belong to the scope of protection claimed in the present invention.

[0032] Example 1 Preparation of Mailuo Shutong Pills

[0033]

[0034] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0035] B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 of the prescribed amount of Leech, Centipede and Scorpion, and combine them with the residue obtained in step A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoctions, filter and set aside;

[0036] C. Combine the aqueous solution after distillation in step A and the decoction in step B, concentrate to obtain a concentrate, add ethanol to make the alcohol content reach 60%-70%, let it stand for 24-36 hours to allow it to fully precipitate, collect the supernatant, filter, concentrate the filtrate under reduced pressure to recover ethanol to obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder;

[0037] D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside;

[0038] E. Mix the fine powder of medicinal materials obtained in step D and the dry powder obtained in step C, add the volatile oil in step A, add an appropriate amount of starch, mix evenly, make pills, and dry.

[0039] Example 2 Preparation of Mailuoshutong Granules

[0040]

[0041] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0042] B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 of the prescribed amount of Leech, Centipede and Scorpion, and combine them with the residue obtained in step A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoctions, filter and set aside;

[0043] C. Combine the aqueous solution after distillation in step A and the decoction in step B, concentrate to obtain a concentrate, add ethanol to make the alcohol content reach 60%-70%, let it stand for 24-36 hours to allow it to fully precipitate, collect the supernatant, filter, concentrate the filtrate under reduced pressure to recover ethanol to obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder;

[0044] D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside;

[0045] E. Mix the medicinal material powder obtained in step D and the dry powder obtained in step C, add the volatile oil in step A, add ethanol as a wetting agent to make a soft material, granulate, put it into a boiling drying bed for drying, spray the volatile oil in step A, directly add appropriate amount of dextrin and sodium carboxymethyl starch (weight ratio 2:1) through conventional procedures, mix, granulate, and dry to obtain granules.

[0046] Example 3 Preparation of Mailuoshutong Tablets

[0047]

[0048] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0049] B. Weigh the prescription amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 prescription amount of Leech, Centipede and Scorpion and combine them with the residue obtained in step A, add water and boil for 3 times, add 11 times amount of water for the first time and boil for 3 hours, add 9 times amount of water for the second time and boil for 2 hours, add 7 times amount of water for the third time and boil for 1 hour, combine the decoctions, filter and set aside;

[0050] C. Combine the aqueous solution after distillation in step A and the decoction in step B, concentrate to obtain a concentrated solution, add ethanol to make the alcohol content reach 70%, let it stand for 24 hours to fully precipitate, collect the supernatant, filter, recover ethanol, concentrate the filtrate under reduced pressure, recover ethanol, obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder for standby use;

[0051] D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside;

[0052] E. Take the dry powder obtained in step C and the fine powder in step D, add appropriate amount of powdered sugar and dextrin to mix, add appropriate amount of ethanol to make a soft material, granulate, dry, spray the volatile oil in step A, add the formulated amount of microcrystalline fiber and hydroxypropyl fiber (weight ratio 4:3) according to the conventional preparation process, mix, granulate, dry, add 0.2% magnesium stearate and 0.1% talcum powder, mix, tablet, and film-coat to obtain tablets.

[0053] Example 4 Preparation of Mailuo Shutong Dropping Pills

[0054]

[0055] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0056] B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 the prescribed amount of Leech, Centipede, Scorpion and

[0057] Combine the residues obtained from A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoction, filter and set aside;

[0058] C. Combine the aqueous solution after distillation in step A and the decoction in step B, concentrate to obtain a concentrated solution, add ethanol to make the alcohol content reach 60%-70%, let it stand for 24-36 hours to allow it to fully precipitate, collect the supernatant, filter, and concentrate the filtrate under reduced pressure to recover

[0059] Ethanol is used to obtain an extract, the extract is vacuum dried to a dry paste, and then crushed into a dry powder;

[0060] D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside;

[0061] E. Mix the fine powder of medicinal materials obtained in step D and the dry powder obtained in step C, add an appropriate amount of polyethylene glycol matrix, heat until melted, add the volatile oil in step A, mix well, and prepare dripping pills.

[0062] Example 5 Preparation of Mailuo Shutong Micropills

[0063]

[0064] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0065] B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 of the prescribed amount of Leech, Centipede and Scorpion, and combine them with the residue obtained in step A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoctions, filter and set aside; C. Combine the aqueous solution after distillation in step A with the decoction in step B, concentrate to obtain a concentrated solution, add ethanol to make the alcohol content reach 60%-70%, stand for 24-36 hours to fully precipitate, collect the supernatant, filter, and concentrate the filtrate under reduced pressure to recover ethanol to obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder;

[0066] D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside;

[0067] E. Add appropriate amount of ethanol to moisten the cyclodextrin inclusion compound of step A, the dry powder of step C and the fine powder of step D, prepare micropellets, sieve and dry.

[0068] Example 6 Preparation of Mailuo Shutong Capsules

[0069]

[0070] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0071] B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 of the prescribed amount of Leech, Centipede and Scorpion, and combine them with the residue obtained in step A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoctions, filter and set aside; C. Combine the aqueous solution after distillation in step A with the decoction in step B, concentrate to obtain a concentrated solution, add ethanol to make the alcohol content reach 60%-70%, stand for 24-36 hours to fully precipitate, collect the supernatant, filter, and concentrate the filtrate under reduced pressure to recover ethanol to obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder;

[0072] D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside;

[0073] E. Add appropriate amount of starch, micro-powder silica gel and low-substituted hydroxypropyl cellulose to the cyclodextrin inclusion compound of step A, the dry powder of step C and the fine powder of step D, mix well, granulate, dry, granulate, fill, polish in a grinder, remove damaged capsules, and obtain capsules.

[0074] Comparative Example 1

[0075]

[0076] Preparation method: Same as Example 1

[0077] Comparative Example 2

[0078]

[0079] Preparation method: Take the above medicinal materials, add water and boil twice, combine the two decoctions, concentrate into a clear paste, add an appropriate amount of sucrose, and prepare into granules according to conventional processes.

[0080] Comparative Example 3

[0081]

[0082] A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use;

[0083] B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix Seed, Licorice and 1 / 2 of the prescribed amount of Scolopendra and Scorpion, and combine them with the residue obtained in step A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoctions, filter and set aside;

[0084] C. Combine the aqueous solution after distillation in step A and the decoction in step B, concentrate to obtain a concentrate, add ethanol to make the alcohol content reach 60%-70%, let it stand for 24-36 hours to allow it to fully precipitate, collect the supernatant, filter, concentrate the filtrate under reduced pressure to recover ethanol to obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder;

[0085] D. Crush the other 1 / 2 amount of centipedes and scorpions into fine powder for later use;

[0086] E. Mix the medicinal material powder obtained in step D and the dry powder obtained in step C, add the volatile oil in step A, add ethanol as a wetting agent to make a soft material, granulate, put it into a boiling drying bed for drying, spray the volatile oil in step A, directly add appropriate amount of dextrin and sodium carboxymethyl starch (weight ratio 2:1) through conventional procedures, mix, granulate, and dry to obtain granules.

[0087] 1. Pharmacodynamics Experiment

[0088] Experimental Example 1 Study on the treatment of nonbacterial prostatitis in rats with Mailuo Shutong preparation

[0089] 1 Materials

[0090] 1.1 Experimental animals

[0091] Male SPF SD rats, weighing 260-300 g, were provided by Lunan Pharmaceutical Group Co., Ltd., animal license: SYXK (Lu) 2018-0008.

[0092] 1.2 Experimental drugs

[0093] The present invention: the pills obtained in specific embodiment 1;

[0094] Comparative Example: Comparative Example 1 obtained pills, Comparative Example 2 obtained granules;

[0095] Positive control group: Qianlieshutong capsule.

[0096] The medicinal materials and preparations used are commonly available on the market, and the product quality complies with national regulations.

[0097] 2 Methods

[0098] 2.1 Modeling and drug administration

[0099] 80 rats were randomly divided into blank group, model group, positive control group, low, medium and high dose groups of embodiment 1, comparative example 1 group, comparative example 2 group, 10 rats in each group, adaptive feeding for 1 week. Rats were anesthetized with ether, fixed on a sterile towel in supine position, depilated and disinfected in the middle of the lower abdomen to open the abdominal cavity, find the prostate on both sides of the bladder, inject 25% of the injection of Xiaozhiling into the prostate 0.1mL / side, the blank group was injected with the same volume of sterile saline in the same position, sutured layer by layer, and the model was formed for 7d, and administration was started after 7d. Positive group rats were given 0.468g / kg of Qianlieshutong capsule aqueous solution by gavage, low, medium and high dose groups of embodiment 1 rats were given 2.34, 4.68, 9.36g / kg of liquid by gavage, comparative example 1 group and comparative example 2 group were given 4.68g / kg of liquid by gavage, and the model group and blank group were given equal volume of sterile saline by gavage, once a day, and continuous administration was 14d.

[0100] 2.2 Index determination

[0101] 2.2.1 Prostate wet weight and prostate index determination

[0102] 2 hours after the last administration, the rats were weighed, blood was collected from the femoral artery and the rats were killed. The prostate was removed and dried with filter paper to obtain the wet mass.

[0103] Prostate index = prostate wet weight mg / body weight g×100

[0104] 2.2.2 Prostate histopathological observation and scoring

[0105] 2 hours after the last administration, the rats were weighed, blood was collected from the femoral artery, and the rats were killed. The prostate was dissected, and part of the prostate tissue was fixed with 4% paraformaldehyde. The prostate tissue fixed with 4% paraformaldehyde was taken, and after routine tissue dehydration, paraffin embedding, sectioning, etc., HE staining was performed, and histopathological observation was performed under a light microscope. No inflammatory cell infiltration in the interstitium, uniform pink secretion in the glandular cavity, was scored 0 points; a small amount of inflammatory cell infiltration in the interstitium and reduced secretion in the glandular cavity was scored 1 point; a large amount of inflammatory cell infiltration in the interstitium, and the secretion in the cavity was significantly reduced and disappeared, was scored 2 points; a large amount of inflammatory cells infiltrated in the prostate interstitium and the tube wall was destroyed, was scored 3 points.

[0106] 2.2.3 Leukocyte count and lecithin body density in prostatic fluid

[0107] 2 hours after the last administration, the rats were weighed, blood was collected from the femoral artery, and the rats were killed. The prostate was dissected, and 0.1 mL of prostatic fluid was drawn with a syringe and placed on a slide. The white blood cell count and the number of lecithin bodies were observed under a high-power microscope (10×40). The density of lecithin bodies was divided into 4 levels according to clinical laboratory standards, that is, full field of view was ++++, 3 / 4 field of view was +++, 1 / 2 was ++, and 1 / 4 field of view was +.

[0108] 2.2.4ELISA for detection of TNF-α and IL-6 levels

[0109] 2 hours after the last administration, the rats were weighed, blood was collected from the femoral artery and then the rats were killed. The prostate was dissected and the prostate tissue was obtained. The TNF-α and IL-6 levels were detected in strict accordance with the instructions of the reagents.

[0110] 2.3 Data processing

[0111] The data were processed using SPSS 22.0 software. The data were compared among the groups using one-way analysis of variance and multiple comparisons, and the graphs were drawn using Sigma Plot 14. P < 0.05 indicated that the difference was statistically significant.

[0112] 3 Results

[0113] 3.1 Effect of prostate wet weight and prostate index

[0114] Table 1 Comparison of prostate indexes in rats of each group

[0115]

[0116]

[0117] Compared with the blank group, * P<0.05, ** P < 0.01;

[0118] Compared with the model group, @ P<0.05, @@ P < 0.01;

[0119] Compared with the Qianlie Shutong capsule group, # P<0.05, ## P < 0.01;

[0120] Compared with the dosage group in Example 1, $ P<0.05, $$ P<0.01.

[0121] As shown in Table 1, compared with the blank group, the prostate mass of the model group increased significantly (P<0.01); compared with the model group, the Qianlie Shutong capsule group, each dosage group of Example 1 and the comparative example 1 and 2 groups can significantly reduce the prostate mass of rats (P<0.01), compared with the blank group, there is no significant difference (P>0.01), compared with the dosage group in Example 1, the comparative example 1 group (P<0.05) and the comparative example 2 group (P<0.01), all show differences. The above results suggest that each dosage group of the embodiment of the present invention can significantly reduce the prostate index of diseased rats, and has a similar effect to the prostate Shutong capsule group.

[0122] 3.2 Changes in rat prostate tissue

[0123] The prostate acinar epithelial cells of the blank group rats were arranged in a single layer of cubic or columnar shape, with pink secretions in the glands, less interstitial tissue, and no proliferation of fibrous tissue; the symptoms of chronic inflammatory cell infiltration, interstitial capillary congestion, and fibrous tissue hyperplasia in the prostate tissue of the model group rats were not improved; the symptoms of chronic inflammation in the prostate tissue of the Qianlie Shutong capsule group, each dose group of Example 1, and the rats in the comparative examples 1 and 2 were alleviated to varying degrees, among which the chronic inflammatory cell infiltration, glandular hyperplasia, and vascular dilation and congestion in the prostate tissue of the rats in the middle dose group of Example 1 were significantly improved, close to the Qianlie Shutong capsule group. It is speculated that the Example 1 group can alleviate the changes in the symptoms of chronic non-bacterial prostate tissue inflammation in rats.

[0124] Table 2 Comparison of prostate tissue lesions in each group of rats

[0125]

[0126]

[0127] 3.3 Effects on lecithin bodies in rat prostatic fluid

[0128] Table 3 Comparison of lecithin bodies in prostatic fluid of rats in each group

[0129]

[0130] Under a high-power microscope, the lecithin bodies are round or quasi-round bodies of varying sizes and strong refractive index, slightly smaller than sperm cells. Under a microscope, it can be seen that the density of the bodies is uniform and translucent. When pathogens or foreign bodies cause prostatitis, the immune system will cause leukocytosis. During the process of phagocytosis, killing and clearing of pathogens or foreign bodies by white blood cells, lecithin bodies are also phagocytosed, resulting in a decrease in lecithin bodies L. Compared with the blank control group, the density of lecithin bodies in the prostate of the model group was reduced; compared with the model group, the middle and high dose groups of the Prostate Shutong Capsules in Example 1 can significantly recover the reduced lecithin body density. It shows that the Example 1 group can significantly increase the number of lecithin bodies in the prostatic fluid, and may have a certain therapeutic effect on prostatitis.

[0131] 3.4 Effect on the white blood cell count in rat prostatic fluid

[0132] Comparison of leukocyte counts in prostatic fluid of rats in each group Figure 1 .

[0133] White blood cells are the main component of blood that participates in the body's immune function and are the body's main line of defense against invasion by foreign bodies such as pathogenic microorganisms. White blood cells can produce various cytokines and initiate inflammatory responses. Clinical research results show that the white blood cell count in the prostatic fluid of patients with chronic prostatitis is significantly higher than that of the normal group. Figure 1 It can be seen that compared with the blank group, the number of leukocytes in the prostate of the model group was significantly increased (P<0.01), compared with the model group, the number of leukocytes in the Prostate Shutong Capsule Group, each dosage group in Example 1, Comparative Example 1 Group and Comparative Example 2 Group was significantly reduced (P<0.01), compared with the dosage group in Example 1, there was a difference between Comparative Example 1 Group and Comparative Example 2 Group (P<0.05), indicating that the Prostate Shutong Capsule Group, each dosage group in the Example and Comparative Examples 1 and 2 Groups can reduce the number of leukocytes in the prostate fluid of rats, and the effect of each dosage group in the Example is equivalent to that of Prostate Shutong Capsule, which is far superior to Comparative Example 1 and Comparative Example 2 Groups.

[0134] 3.5 Comparison of TNF-α and IL-6 in prostate tissue of rats in each group

[0135] Table 4 Changes of TNF-α and IL-6 levels in prostate tissue of rats in each group

[0136]

[0137] Compared with the blank group, * P<0.05, ** P < 0.01;

[0138] Compared with the model group, @ P<0.05, @@ P < 0.01;

[0139] Compared with the Qianlie Shutong capsule group, # P<0.05, ## P < 0.01;

[0140] Compared with the dosage group in Example 1, $ P<0.05, $$ P<0.01.

[0141] TNF-α is a pro-inflammatory cytokine, produced under the action of factors such as infection, which can increase the expression of nitric oxide synthase and prostaglandins, further exacerbating the inflammatory response of prostate tissue, and IL-6 is an anti-inflammatory cytokine that can downregulate the synthesis of inflammatory factors such as TNF-α. As shown in Table 4, compared with the blank group, the level of the model group was significantly increased (P<0.01), and compared with the model group, the levels of the positive control group, each dose group of Example 1, and the comparative examples 1 and 2 were significantly decreased (P<0.01), indicating that the effects of each dose group of Example 1 and the positive control group are almost similar, and may have the effect of reducing inflammatory factors and relieving inflammation in rats.

[0142] Experimental Example 2 Study on the treatment of bacterial prostatitis in rats with Mailuo Shutong preparation

[0143] 1 Materials

[0144] 1.1 Experimental animals

[0145] Male Wistar rats, weighing 200–220 g, were provided by Jinan Pengyue Experimental Animal Breeding Co., Ltd., animal license: SCXK(Lu)20190003.

[0146] 1.2 Experimental drugs and strains

[0147] The present invention: the granules obtained in Specific Example 2, the tablets obtained in Specific Example 3, and the capsules obtained in Specific Example 6;

[0148] Comparative Example: Comparative Example 1 obtained pills, Comparative Example 2 obtained granules;

[0149] Positive control group: Prostate tablets.

[0150] Strains: Escherichia coli (hereinafter referred to as E. coli) and other experimental bacteria were provided by Shandong New Era Pharmacology Center.

[0151] The medicinal materials and preparations used are commonly available on the market, and the product quality complies with national regulations.

[0152] 2 Methods

[0153] 2.1 Modeling and drug administration

[0154] 80 rats were randomly divided into a blank group, a model group, a positive control group, an example 2 group, an example 3 group, an example 6 group, a comparative example 1 group, and a comparative example 2 group, with 10 rats in each group, and were adaptively fed for 1 week. After successful anesthesia with 1% sodium pentobarbital 30 mg / kg, each rat in the model group was injected with 1.5×10 7 CFU / mL of Escherichia coli physiological saline 0.1mL, the blank group was injected with 0.1mL of physiological saline in the same way, the model was formed for 7d, and the administration began after 7d. The positive group rats were gavaged with 0.858g / kg of Qianlietai tablets aqueous solution, Example 2 group, Example 3 group, Example 6 group, Comparative Example 1 group, and Comparative Example 2 group were respectively administered 7.8g / kg, and the model group and the blank group were gavaged with an equal volume of sterile physiological saline, once a day, for 14d. 2h after the last administration, the rats were weighed, and the rats were killed after blood was taken from the femoral artery.

[0155] 2.2 Index determination

[0156] 2.2.1 Urine volume measurement

[0157] Urine volume was measured on the 6th day of drug administration. Rats in each group were fasted for 12 hours and had free access to water. Rats in the blank group and model group were gavaged with 5 mL of normal saline each, and the drug group was gavaged with an equal amount of normal saline with drugs. One rat was placed in each metabolic cage. Before placing the rat, the lower abdomen of the animal was gently pressed to drain the remaining urine, and urine was collected for 1, 2, and 3 hours.

[0158] 2.2.2 White blood cell count and bacterial colony count

[0159] 2 hours after the last administration, the rats were weighed and blood was taken from the femoral artery before being killed. The rats were quickly cut open under sterile conditions, the prostate was removed, the left lobe was cut into pieces and placed in a sterile test tube, 3 ml of normal saline was added for rinsing, the rinsing fluid was centrifuged and the precipitate was taken for bacterial culture identification; 5 mg of right lobe prostate tissue was added to 0.4 ml of a 1:1 mixture of white blood cell diluent and normal saline, the smear was examined under a microscopic microscope, the number of white blood cells was counted and the rat prostate massage fluid was taken.

[0160] 2.3 Data processing

[0161] The data were processed using SPSS 22.0 software. , indicates that the comparison among the groups was performed by one-way analysis of variance and multiple comparisons were performed, and the graph was drawn by Sigma Plot 14. P < 0.05 indicates that the difference is statistically significant.

[0162] 3 Results

[0163] 3.1 Effect on urine output in rats

[0164] Comparison of urine volume among groups of rats Figure 2 .

[0165] Compared with the blank group, the urine volume of rats in the model group decreased (P < 0.01). Compared with the model group, the urine volume of rats in the Qianlietai tablets group and Example 2, Example 3, Example 6 and Comparative Example 1 and 2 groups can all increase (P < 0.01), and as time increases, the effects of each example group and the Qianlietai tablets group are equivalent. The embodiments of the present invention have a certain diuretic effect, can increase the urine volume of rats, and may have a certain therapeutic effect on prostatitis.

[0166] 3.2 Effects on acute bacterial prostatitis in rats

[0167] Table 5 Comparison of acute bacterial prostatitis indexes in rats of each group

[0168]

[0169] Compared with the blank group, @ P<0.05, @@ P < 0.01;

[0170] Compared with the model group, # P<0.05, ## P < 0.01;

[0171] Compared with the Prostaphylococcus group, $ P<0.05, $$ P < 0.01;

[0172] Compared with Example 2, * P<0.05, ** P<0.01.

[0173] It can be seen from the above table that compared with the model group, the number of white blood cells and the number of colonies in the Prosta tablets and the groups of embodiments of the present invention were significantly reduced (P < 0.01). The Prosta tablets and the groups of embodiments of the present invention had a significant inhibitory effect on prostatitis in rats, which was manifested in reducing the number of white blood cells and inhibiting the growth of Escherichia coli in the prostate.

[0174] Experimental Example 3 Study on the treatment of prostatic hyperplasia in rats with Mailuoshutong preparation

[0175] 1.1 Experimental animals

[0176] Male SD rats, clean grade, weighing 260-300 g, were provided by Lunan Pharmaceutical Group Co., Ltd., animal license: SYXK (Lu) 2018-0008.

[0177] 1.2 Experimental drugs and strains

[0178] The present invention: the pills obtained in Specific Example 1, the dripping pills obtained in Specific Example 4, and the micropellets obtained in Specific Example 5;

[0179] Comparative Examples: the pills obtained in Comparative Example 1 and the granules obtained in Comparative Example 3;

[0180] Positive control group: Longbishu capsule.

[0181] The medicinal materials and preparations used are commonly available on the market, and the product quality complies with national regulations.

[0182] 2 Methods

[0183] 2.1 Modeling

[0184] SD male rats were fed adaptively for 1 week. After normal observation without abnormality, male rats were anesthetized intraperitoneally with ketamine hydrochloride injection at 100 mg / kg. After successful anesthesia, the rats were fixed on the operating table, the skin was routinely disinfected, and the bilateral testicles were removed through the scrotum under aseptic conditions. The stumps were ligated to ensure hemostasis and the skin was sutured. After 1 week of observation, each rat was subcutaneously injected with testosterone propionate 3.5 mg / kg according to body weight, once a day, and the drug was administered continuously for 30 days, and the model was successfully established.

[0185] 2.2 Grouping and Dosing

[0186] 2.2.1 Grouping

[0187] Ten rats without modeling were selected as the blank group and performed sham surgery, and the remaining rats were used to establish a prostate hyperplasia model. 70 rats with successful modeling were selected and randomly divided into a model group, a positive control group (Longbishu Capsule group), a specific embodiment 1 group, a specific embodiment 4 group, a specific embodiment 5 group, a comparative example 1 group, and a comparative example 3 group.

[0188] 2.2.2 Administration

[0189] The positive group rats were gavaged with 0.234 g / kg of Longbishu capsule suspension, the specific example 1 group, the specific example 4 group, the specific example 5 group, the comparative example 1 group, and the comparative example 3 group were gavaged with 4.68 g / kg, and the model group and the blank group were gavaged with an equal volume of sterile saline, once a day, for 30 consecutive days. 2 hours after the last administration, the rats were weighed, blood was collected from the femoral artery, and the rats were killed to obtain prostate tissue for testing.

[0190] 2.3 Index determination

[0191] 2.3.1 Prostate wet weight and prostate index

[0192] 2 hours after the last administration (fasting but not water deprivation for 12 hours), the rats were weighed, the prostate was quickly removed and its wet weight was weighed, and the prostate index was calculated (prostate index = prostate wet weight mg / rat body weight g).

[0193] 2.3.2 Testing for testosterone, estradiol and testosterone

[0194] The prostate was divided into two parts, 300 mg of the left lobe of the prostate was weighed, 1 mL of ice saline was added, homogenized at 4°C, centrifuged at 3000 rpm for 15 min, and the supernatant of the prostate tissue homogenate was taken to determine testosterone and testosterone in the prostate tissue.

[0195] 3 Data processing

[0196] The data were processed using SPSS 22.0 software. The differences were statistically significant when P < 0.05.

[0197] 4 Results

[0198] 4.1 Effects on prostate wet weight and prostate index in rat prostatic hyperplasia model

[0199] Table 6 Comparison of prostate index in each group of rat prostate hyperplasia model

[0200]

[0201] Compared with the blank group, @ P<0.05, @@ P < 0.01;

[0202] Compared with the model group, # P<0.05, ## P < 0.01;

[0203] Compared with the Longbishu capsule group, $ P<0.05, $$ P < 0.01;

[0204] Compared with the specific embodiment 1 group, * P<0.05, ** P<0.01.

[0205] Compared with the blank group, the prostate index in the model group was significantly increased (P<0.01). Compared with the model group, the Longbishu capsule group, the specific embodiment groups and the comparative embodiment group could significantly reduce the prostate index, which may have a certain inhibitory effect on prostate hyperplasia.

[0206] 4.2 Effects of testosterone and testosterone on prostatic hyperplasia in rats

[0207] Table 7 Comparison of testosterone and testosterone in each group of rats with prostatic hyperplasia model

[0208]

[0209]

[0210] Compared with the blank group, @ P<0.05, @@ P < 0.01;

[0211] Compared with the model group, # P<0.05, ## P < 0.01;

[0212] Compared with the Longbishu capsule group, $ P<0.05, $$ P < 0.01;

[0213] Compared with the specific embodiment 1 group, * P<0.05, ** P<0.01.

[0214] Compared with the blank group, the testosterone and testosterone content of the rats in the model group were significantly increased (P<0.01). The Longbishu Capsule group, the groups of the specific embodiments and the groups of the comparative embodiments can significantly inhibit the increase of testosterone levels (P<0.01), and the results of the groups of the embodiments of the present invention and the positive control group are comparable, which has a certain therapeutic effect on prostate hyperplasia.

Claims

1. Use of the Mailuo Shutong preparation in preparing drugs for treating prostate diseases, wherein the Mailuo Shutong preparation is made of 12 raw materials: astragalus, honeysuckle, phellodendron, atractylodes, scrophularia, angelica, white peony root, coix seed, centipede, scorpion, leech, and licorice.

2. The use according to claim 1, characterized in that The prostate diseases include but are not limited to prostatitis, prostate hyperplasia and prostate cysts.

3. The use according to claim 2, characterized in that The prostatic hyperplasia is divided into blood stasis in the lower part of the body type, bladder damp-heat type, kidney yin deficiency type, kidney yang deficiency type or lung heat and qi stagnation type according to TCM dialectics, and the prostatitis is divided into damp-heat descending type, qi stagnation and blood stasis type, yin deficiency and hyperactivity of fire type, kidney yang deficiency type or spleen deficiency and dampness type according to TCM dialectics.

4. The use according to claim 3, characterized in that The prostatitis includes, but is not limited to, acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis / chronic pelvic pain syndrome and asymptomatic prostatitis.

5. The use according to claim 2, characterized in that The Mailuo Shutong preparation is mainly prepared from the following raw materials: 400-900 parts by weight of Astragalus, 400-900 parts by weight of Honeysuckle, 200-500 parts by weight of Phellodendron, 200-500 parts by weight of Atractylodes, 400-900 parts by weight of Coix Seed, 400-900 parts by weight of Scrophularia, 200-500 parts by weight of Angelica, 200-500 parts by weight of White Peony, 200-500 parts by weight of Licorice, 50-150 parts by weight of Leech, 200-500 parts by weight of Centipede, and 50-150 parts by weight of Scorpio.

6. The use according to claim 5, characterized in that The Mailuo Shutong preparation is mainly prepared from the following raw materials: 833 parts by weight of Astragalus, 833 parts by weight of Honeysuckle, 417 parts by weight of Phellodendron, 417 parts by weight of Atractylodes, 833 parts by weight of Coix Seed, 833 parts by weight of Scrophularia, 833 parts by weight of Angelica, 417 parts by weight of White Peony, 417 parts by weight of Licorice, 138 parts by weight of Leech, 417 parts by weight of Centipede, 33 parts by weight of Scorpio, and 138 parts by weight of Whole Scorpion.

7. The use according to claim 5, characterized in that The Mailuo Shutong preparation is mainly prepared from the following raw materials: 500 parts by weight of Astragalus, 500 parts by weight of Honeysuckle, 250 parts by weight of Phellodendron, 250 parts by weight of Atractylodes, 500 parts by weight of Coix Seed, 500 parts by weight of Scrophularia, 250 parts by weight of Angelica, 250 parts by weight of White Peony, 83 parts by weight of Licorice, 250 parts by weight of Leech, 20 parts by weight of Centipede, and 83 parts by weight of Scorpion.

8. The use according to any one of claims 1 to 7, characterized in that The Mailuo Shutong preparation is prepared by the following method: the raw medicinal material pieces are subjected to steam distillation, water decoction, and ethanol reflux extraction to obtain an extract, the extract is dried and crushed, mixed with fine powder of animal medicinal materials, and pharmaceutically acceptable excipients are added to prepare a clinically acceptable dosage form.

9. The use according to claim 8, characterized in that The described Pathogenic Shutong preparation is prepared by the following method: A. Weigh the prescribed amount of honeysuckle, atractylodes, Scrophularia, Chinese angelica, and white peony root slices, add water and distill for 6 to 8 hours, collect the volatile oil, and use the distilled aqueous solution and drug residues for later use; B. Weigh the prescribed amount of Astragalus, Phellodendron, Coix seeds, Licorice and 1 / 2 of the prescribed amount of Leech, Centipede and Scorpion, and combine them with the residue obtained in step A, add 6-12 times the amount of water and boil for 2-3 times, each time for 1-3 hours, combine the decoctions, filter and set aside; C. Combine the aqueous solution after distillation in step A and the decoction in step B, concentrate to obtain a concentrate, add ethanol to make the alcohol content reach 60%-70%, let it stand for 24-36 hours to allow it to fully precipitate, collect the supernatant, filter, concentrate the filtrate under reduced pressure to recover ethanol to obtain an extract, vacuum dry the extract to a dry paste, and grind it into dry powder; D. Crush the remaining 1 / 2 amount of leeches, centipedes and scorpions into fine powder and set aside; E. Mix the fine powder of medicinal material obtained in step D and the dry powder obtained in step C, add the volatile oil in step A, and prepare a clinically acceptable dosage form directly or by adding pharmaceutically acceptable excipients through conventional procedures.

10. The use according to claim 8, characterized in that The clinically acceptable dosage form is one or more of pills, granules, tablets, pellets, micropills, and capsules; further preferably, the preparation is pills or granules; more preferably, the preparation is Mailuo Shutong pills or Mailuo Shutong granules.